Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Sarcoma 6Cardiotoxicity 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 3Neuroblastoma 2Leukemia 2Vomiting 1Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Nausea 1Lymphoma, Large-Cell, Anaplastic 1Localized Extraskeletal Ewing Sarcoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Ganglioneuroblastoma 1Fibrosarcoma 1Extravasations of Anthracycline Anti-cancer Agents 1Extravasation 1Drug-Related Side Effects and Adverse Reactions 1Dermatofibrosarcoma 1Degradation of Top2b and Top2a in Human by Dexrazoxane 1

Interventions

Vincristine 3Topotecan 3Stem Cell Transplantation 3Radiation 3Platinum 3Melphalan 3Doxorubicin 3Cyclophosphamide 3Congresses as Topic 3Cisplatin 31,2-diaminocyclohexaneplatinum II citrate 3sargramostim 2dinutuximab 2Isotretinoin 2Etoposide 2Colony-Stimulating Factors 2Busulfan 2temsirolimus 1etoposide phosphate 1Thiotepa 1Temozolomide 1Sirolimus 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Peripheral Blood Stem Cell Transplantation 1Mesna 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ganglioneuroblastoma × Dexrazoxane × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡